U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07402343) titled 'Tarlatamab for SCLC Brain Metastases' on Jan. 15.
Brief Summary: A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Small Cell Lung Cancer
Brain Metastases, Adult
Intervention:
DRUG: Tarlatamab
Cycle 1: 1 mg on day 1, followed by 10 mg on days 8 and 15 Cycles thereafter: 10 mg every two weeks, in cycles of 28 days Treatment continues till unacceptable toxicity or disease progression
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Maastricht Unive...